SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma

New findings highlight the therapy’s ability to preferentially destroy MGMT-positive tumor cells, the specific population that survives standard treatments and drives disease recurrence.

TAIPEI, Taiwan, Sept. 24, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced new preclinical data evaluating unmodified human γδ T cells in glioblastoma (GBM) — the Company’s unmodified γδ T cell therapy platform (the “GDT platform”). The findings are being presented as poster P-2017 at the 85th Annual Meeting of the Japanese Cancer Association, held from September 24–26, 2026. The research was conducted in collaboration with investigators at Taipei Medical University (TMU), JY BioMed, and HeXun Biosciences.